Project Grant R35GM155362
Award Date
8/1/24
Completion Date
5/31/29
Dollars Obligated
$1.1M
Federal Agency
National Institute of General Medical Sciences
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Binghamton, NY 13902, USA
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $1,640,169 to Synvivia, Inc. to validate a platform for identifying cyclic peptides that can dramatically increase the yield and quality of adeno-associated virus (AAV) vectors manufactured for gene therapy. The key objectives are to: 1) demonstrate that Synvivia's cyclic peptide discovery library contains molecules that...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $540,524 to the University of Massachusetts Medical School (UMass Medical) from March 1, 2025 to February 28, 2029. The project aims to develop an enhanced synthetic RNA switch to precisely control transgene expression in adeno-associated viral (AAV) gene therapies. Key...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) seeks to establish a versatile platform for delivering RNA to the central nervous system (CNS). The project aims to develop an RNA delivery system with high efficiency, precise cell-specific targeting, and minimal cellular disruption. Key objectives include engineering RNA-encapsulating capsids, optimizing capsid surface engineering...
This Project Grant award of $388,621 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support the development of novel molecular designs with therapeutic potential. The key objectives are: Developing ligand-heterocycle conjugates as targeted RNA degraders with rapid kinetics and selectivity for cancer-associated G-quadruplexes. Engineering nucleic acid polymers with (thio)phosphoramidate backbones as biostable...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded Cornell University a $435,412 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The goal of this 2-year project is to develop a biomaterial-driven, immunosuppressive platform that enables the re-administration of engineered adeno-associated virus (AAV) gene delivery vectors while maintaining their transduction efficiency....
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $364,167 to Villanova University to develop novel non-viral gene delivery methods for cell therapies. The key objectives are: The Bracaglia Lab will develop new polymeric gene delivery vehicles to improve the delivery of siRNAs and other payloads to T cells and hematopoietic stem cells (HSCs). Drs. Elmer and Huang will...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $284,331 to the University of Massachusetts Medical School (UMass Medical) to conduct research on the stability of gene therapy vectors based on adeno-associated virus (AAV) when challenged by natural viral infections. The objectives of this 2-year project are to: 1) Develop an in vitro model to track changes...
This $325,000 project grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) will support the development and testing of a new class of programmable, non-viral gene therapy carriers and cargo known as virus-inspired DNA origami (VIDO) vectors and repair templates. The project aims to demonstrate that VIDO vectors can effectively encapsulate and co-deliver CRISPR-Cas9 gene editing agents and repair...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $769,737 to Yale University to develop capsid-engineered adeno-associated viral (AAV) vectors that can specifically target and deliver gene therapies to human T cells and myeloid cells. The goal is to use these AAV vectors to deliver a designer recombinase called BREC1, which can eliminate HIV provirus integrated in...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $487,499 to the Whitehead Institute for Biomedical Research to develop new strategies for highly efficient production of cell-derived bioparticles as delivery vehicles for macromolecular therapeutics. The research aims to identify and manipulate genes in bioparticle producer cells to enhance production efficiency, and establish a...